Search research articles
Contact Us
Filters
Showing results (1-10 of 5) with videos related to
Page
of 1
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
February 6, 2022
SOHO State of the Art Updates and Next Questions: Managing Relapsed Mantle Cell Lymphoma
Jason T Romancik, Drew G Gerber, Tony Zhuang, et al.
Brachytherapy
|
January 13, 2026
MRI-guided neurovascular bundle avoidance in high dose rate prostate brachytherapy
Drew G Gerber, Sean Dresser, Xiaofeng Yang, et al.
Molecular Cancer Research : MCR
|
March 14, 2019
E-Cadherin Represses Anchorage-Independent Growth in Sarcomas through Both Signaling and Mechanical Mechanisms
Mohit Kumar Jolly, Kathryn E Ware, Shengnan Xu, et al.
Cancer Discovery
|
April 10, 2022
PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Benoit Rousseau, Ivan Bieche, Eric Pasmant, et al.
Blood Cancer Journal
|
April 25, 2026
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy
Yucai Wang, Melissa C Larson, Steven R Hwang, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 5) with videos related to
Sort By:
Page
of 1
Clinical Lymphoma, Myeloma & Leukemia
|
February 6, 2022
SOHO State of the Art Updates and Next Questions: Managing Relapsed Mantle Cell Lymphoma
Jason T Romancik, Drew G Gerber, Tony Zhuang, et al.
Brachytherapy
|
January 13, 2026
MRI-guided neurovascular bundle avoidance in high dose rate prostate brachytherapy
Drew G Gerber, Sean Dresser, Xiaofeng Yang, et al.
Molecular Cancer Research : MCR
|
March 14, 2019
E-Cadherin Represses Anchorage-Independent Growth in Sarcomas through Both Signaling and Mechanical Mechanisms
Mohit Kumar Jolly, Kathryn E Ware, Shengnan Xu, et al.
Cancer Discovery
|
April 10, 2022
PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Benoit Rousseau, Ivan Bieche, Eric Pasmant, et al.
Blood Cancer Journal
|
April 25, 2026
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy
Yucai Wang, Melissa C Larson, Steven R Hwang, et al.
Page
of 1